Louise Chen
Stock Analyst at Scotiabank
(3.39)
# 995
Out of 5,090 analysts
300
Total ratings
46.48%
Success rate
3.9%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Initiates: Sector Outperform | $35 | $28.36 | +23.44% | 4 | Dec 5, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Sector Perform | $45 → $53 | $52.14 | +1.65% | 1 | Dec 4, 2025 | |
| MRK Merck & Co. | Maintains: Sector Outperform | $105 → $120 | $101.47 | +18.27% | 26 | Dec 4, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Sector Perform | $650 → $770 | $732.00 | +5.19% | 2 | Nov 24, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $22.60 | +253.98% | 3 | Jun 6, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $2.98 | +202.01% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $24.16 | -42.05% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $3.60 | +233.33% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $20.89 | +163.28% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $77.32 | -28.87% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $2.39 | +527.62% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $98.09 | -49.03% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $15 | $5.81 | +158.40% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $39.14 | -56.57% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $71.68 | -2.34% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $20.89 | +139.35% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $9.94 | +201.81% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $19.83 | +177.43% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.28 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $48.71 | +228.47% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $45.66 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $240 | $226.76 | +5.84% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.74 | +74.83% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $202.88 | +5.97% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.65 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $21.09 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $1,017.14 | -12.99% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.84 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $23.03 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.81 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.59 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $220.63 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.77 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.21 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.46 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.88 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.66 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.41 | +1,806.16% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $2.42 | +106.61% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $14.21 | +251.93% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $30.75 | +62.60% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.63 | +207.16% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $0.39 | +2,232.21% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $1.10 | +153,408,990.91% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $283.25 | -8.91% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $1.27 | +3,837.01% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.35 | +1,386.99% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $8.01 | +461.80% | 1 | Jun 22, 2017 |
Teva Pharmaceutical Industries
Dec 5, 2025
Initiates: Sector Outperform
Price Target: $35
Current: $28.36
Upside: +23.44%
Bristol-Myers Squibb Company
Dec 4, 2025
Maintains: Sector Perform
Price Target: $45 → $53
Current: $52.14
Upside: +1.65%
Merck & Co.
Dec 4, 2025
Maintains: Sector Outperform
Price Target: $105 → $120
Current: $101.47
Upside: +18.27%
Regeneron Pharmaceuticals
Nov 24, 2025
Maintains: Sector Perform
Price Target: $650 → $770
Current: $732.00
Upside: +5.19%
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $22.60
Upside: +253.98%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $2.98
Upside: +202.01%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $24.16
Upside: -42.05%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $3.60
Upside: +233.33%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $20.89
Upside: +163.28%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $77.32
Upside: -28.87%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $2.39
Upside: +527.62%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $98.09
Upside: -49.03%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $5.81
Upside: +158.40%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $39.14
Upside: -56.57%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $71.68
Upside: -2.34%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $20.89
Upside: +139.35%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $9.94
Upside: +201.81%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.83
Upside: +177.43%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.28
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $48.71
Upside: +228.47%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $45.66
Upside: -
Oct 31, 2024
Maintains: Overweight
Price Target: $200 → $240
Current: $226.76
Upside: +5.84%
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.74
Upside: +74.83%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $202.88
Upside: +5.97%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.65
Upside: -
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $21.09
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $1,017.14
Upside: -12.99%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.84
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $23.03
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.81
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.59
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $220.63
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.77
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.21
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.46
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.88
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.66
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.41
Upside: +1,806.16%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $2.42
Upside: +106.61%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $14.21
Upside: +251.93%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $30.75
Upside: +62.60%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.63
Upside: +207.16%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $0.39
Upside: +2,232.21%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $1.10
Upside: +153,408,990.91%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $283.25
Upside: -8.91%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $1.27
Upside: +3,837.01%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.35
Upside: +1,386.99%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $8.01
Upside: +461.80%